Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

Hang Quach; Liam Fernyhough; Ross Henderson; Gillian Corbett; Bart Baker; Peter Browett; Hilary Blacklock; Cecily Forsyth; Craig Underhill; Paul Cannell; Judith Trotman; Annette Neylon; Simon Harrison; Emma Link; Arlene Swern; Linda Cowan; Meletios A Dimopoulos; H Miles Prince

Journal article

Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study

Hang Quach, Liam Fernyhough, Ross Henderson, Gillian Corbett, Bart Baker, Peter Browett, Hilary Blacklock, Cecily Forsyth, Craig Underhill, Paul Cannell, Judith Trotman, Annette Neylon, Simon Harrison, Emma Link, Arlene Swern, Linda Cowan, Meletios A Dimopoulos, H Miles Prince

British Journal of Haematology | WILEY | Published : 2017

DOI: 10.1111/bjh.14562

University of Melbourne Researchers

Hang Quach Author Medical Education

Emma Link Author The Sir Peter MacCallum Department of Oncology

Henry Prince Author Medicine - St Vincent's Hospital

Hang Quach Author Medicine - St Vincent's Hospital

Simon Harrison Author The Sir Peter MacCallum Department of Oncology

Grants

Funding Acknowledgements

We acknowledge the Vincent Fairfax Research Scholarship awarded to Hang Quach from the Royal Australasian College of Physicians that partially funded this clinical trial. We sincerely thank Dr Jack Shiansong Li's support for the data extraction of patients from the MM009/MM010 trials.